SCHEMBL16827460

SCHEMBL16827460

Cc1cccc(OC(C)(C)I)c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 2/20 0.54
▸ ALDH1A1 P00352 2/20 0.48
▸ LMNA P02545 1/20 0.46
▸ HTT P42858 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ GAA P10253 2/20 0.42
▸ AR P10275 2/20 0.41
▸ DRD2 P14416 1/20 0.40
▸ DRD4 P21917 1/20 0.40
▸ DRD3 P35462 1/20 0.40
▸ CHRM5 P08912 1/20 0.39
▸ RELA Q04206 1/20 0.38
▸ SLC6A2 P23975 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16363563 0.84 ACHE (0.50) ACHEALDH1A1LMNAHTTTDP1
SCHEMBL7386225 0.83 ACHE (0.58) ACHEALDH1A1LMNAHTTTDP1
SCHEMBL19375277 0.82 ACHE (0.52) ACHEALDH1A1LMNAHTTTDP1
SCHEMBL3393561 0.81 ACHE (0.56) ACHEALDH1A1LMNAHTTTDP1
SCHEMBL28963146 0.80 ACHE (0.60) ACHEALDH1A1LMNAHTTTDP1
SCHEMBL7561328 0.79 ACHE (0.54) ACHEALDH1A1LMNAHTTTDP1
SCHEMBL20462014 0.79 ACHE (0.54) ACHEALDH1A1LMNAHTTTDP1
SCHEMBL20752042 0.79 ACHE (0.54) ACHEALDH1A1LMNAHTTTDP1
SCHEMBL8460171 0.79 ACHE (0.54) ACHEALDH1A1LMNAHTTTDP1
SCHEMBL11685732 0.77 ACHE (0.56) ACHEALDH1A1LMNAHTTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015092634-A1 1,2,3,4-TETRAHYDROISOQUINOLINE COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR ANTAGONISTS AND DEGRADERS NOVARTIS AG (CH) 2015-06-25 — — WO disclosed
Send feedback